EU/3/16/1691

About

On 14 July 2016, orphan designation (EU/3/16/1691) was granted by the European Commission to Pfizer Limited, United Kingdom, for 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid for the treatment of Huntington's disease.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2018 on request of the Sponsor.

Key facts

Active substance
2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid
Disease / condition
Treatment of Huntington's disease
Date of decision
14/07/2016
Outcome
Withdrawn
Orphan decision number
EU/3/16/1691

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom
Tel. +44 (0)1304 616 161
Fax +44 (0)1304 652 144
E-mail: orphan_enquiries@pfizer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating